anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention relates to veterinary medecine and can be used to prevent tuberculosis, a contagious disease common to humans and animals. The method of preventing tuberculosis in young cattle includes the step of making intramuscular injections of a preventive formulation and of an immunomodulator. The preventive formulation is tuberculin (PPD tuberculin) and the immunomodulator is a formulation containing (in weight percent) 0.07-0.1 of formaldehyde and 0.9-0.95 of sodium chloride, the rest being composed of distilled water. First, tuberculin is injected in one time to young cattle of colostrum age, each dosage comprising 3-4 ml per head of cattle, and 30-40 minutes later the immunomodulator is injected, each dosage comprising 4-6 ml per head. The proposed method of preventing tuberculosis in young cattle provides calves with high resistance to the tuberculosis pathogen agent both in permanently disadvantaged farms and in those being focuses of acute disease. The method permits to create droves of sane heifers from the animals of one's own farm in order to replace livestock having problems. Moreover, the use of this method solves the problem of further diagnostics of this disease in immunized animals.
The invention provides a phascolosoma esculenta plasmin gene, phascolosoma esculenta recombinant plasmin and application of phascolosoma esculenta recombinant plasmin. The sequence of the phascolosoma esculenta plasmin gene is shown in SEQ ID NO:1. Through a protein expression system, recombinant protein inducible expression is performed on the phascolosoma esculenta plasmin gene to obtain the phascolosoma esculenta recombinant plasmin. The amino acid sequence of phascolosoma esculenta recombinant plasmin is shown in SEQ ID NO:2. According to the application of phascolosoma esculenta recombinant plasmin, the phascolosoma esculenta plasmin gene is used for preparing thrombolytic drug and treating the thrombus disease. The phascolosoma esculenta plasmin gene and phascolosoma esculenta recombinant plasmin have the capacity of directly dissolving fiber protein in blood dots, when the fiber protein is degraded, an alpha chain is first degraded, then a beta chain is degraded, a gamma chain is finally degraded, and the phascolosoma esculenta plasmin gene is alpha-plasmin and has a certain effect on restraining tumor cells.
Space travel has transformed in the past several years. Given the burgeoning market for space tourism, in-flight medical emergencies are likely to be expected. Ultrasound is one of the few diagnostic and therapeutic modalities available for astronauts in space. However, while point-of-care ultrasound (POCUS) is available, there is no current standard of training for astronaut preparation. We suggest an organized and structured methodology by which astronauts should best prepare for space with the medical equipment available on board. As technology continues to evolve, the assistance of other artificial intelligence and augmented reality systems are likely to facilitate training and dynamic real-time needs during space emergencies. Summary: As space tourism continues to evolve, an organized methodology for POCUS use is advised to best prepare astronauts for space.
This is a prospective study to evaluate the efficacy and safety of an accessory for laser tattoo removal in allowing multiple passes within a single treatment session. One half of the tattoo will be randomly assigned laser treatment utilizing the Device (the "Device half"); the other half will receive laser treatment without the Device and serve as the control (the "Control half"). Based on statistical analysis sample size calculations, 30 subjects will be enrolled. The tattoo must be no larger than approximately 2 ½" x 6" or 3" x 5" in size, such that ½ of the tattoo can be covered with a single patch. Each subject will receive a single Treatment Session consisting of 5 minutes. Investigators will administer the standard laser treatment to both the Device and Control sites using well-established tattoo-removal treatment parameters for the laser used. Subjects will return for follow up approximately one month post-treatment. The presence of side effects and adverse events will be assessed and recorded for both Device and Control sites immediately after treatment and at the 1-month follow-up visit.
FIELD: biologically active compounds. SUBSTANCE: new 22-thiavitamin D 3  derivatives with general formula I:   (I) wherein R 1  is C 1 -C 10 -alkyl optionally substituted by hydroxyl group, R 2  hydrogen atom or hydroxyl, and R 3  hydroxyl. Vitamins show wide spectrum of physiologic activities. Intermediate products and synthetic procedures are also described. Derivatives of vitamins substituted by sulfur atom in position 22 exhibit strong inhibiting effect with respect to proliferation of keratinocytes. EFFECT: extended physiologic activities. 36 cl, 5 dwg, 91 ex
TAVT-45 administered twice daily as a 1 x sachet containing TAVT-45 (250 mg abiraterone acetate) + Prednisone (5mg once or twice daily, depending on prostate cancer population). TAVT-45 administered approximately every 12 hours without respect to food. Patients treated for 84 days.
Objective: To understand the situation and epidemic characteristics of injury deaths among children aged 5 to 24 years in Jiangsu Province from 2012 to 2021 and the trend of annual changes. Methods: The main injury mortality data of children and adolescents was collected, and the crude and standardized mortality rates of road traffic accidents, drowning, suicide, and accidental falls among children and adolescents over a decade and the annual average percentage of change (AAPC) were calculated. The main injury mortality characteristics and trends of children and adolescents of different age groups and genders were analyzed. Results: The total number of injury deaths among 5 to 24 adolescents in Jiangsu Province was 16 052, with a standardized mortality rate of 9.58/100 000. There was no significant trend in the overall standardized mortality rate of injuries (AAPC=-3.450%, P=0.055). The standardized mortality rate of road traffic injuries among children and adolescents showed a decreasing trend over the past decade, with statistical significance (AAPC=-9.406%, P<0.001). The standardized suicide mortality rate showed an upward trend over the past decade, with statistical significance (AAPC=9.000%, P=0.001). The overall injury mortality rate showed an upward trend with age. Suicide rates in males and females were on the rise and both have statistical significance (AAPC=9.420% and AAPC=9.607%, both P<0.05). The standardized mortality rates of female traffic accidents, drowning, and male traffic accidents showed a decreasing trend and were statistically significant (AAPC for female traffic accidents=-7.364%, AAPC for female drowning=-5.352%, and AAPC for male traffic accidents=-10.242%, all P<0.05). The standardized mortality rate of urban and rural traffic accidents showed a decreasing trend and was statistically significant(AAPC=-7.899% and AAPC=-9.421%, both P<0.001). The standardized suicide mortality rate showed an upward trend and statistical significance (AAPC=11.009% and AAPC=7.528%, both P<0.05). Conclusions: The overall injury situation of children and adolescents in Jiangsu Province improved in the past decade from 2012 to 2021, but the suicide mortality rate was on the rise. It is necessary to focus on the mental health issues of this age group and to strengthen the prevention and control of suicide among children and adolescents, in Jiangsu.
Participants will ingest diazoxide oral suspension at 1 mg per kg body weight per dose (27 doses over 14 days). Blinding will occur by completely covering single-dose oral syringes with labels.
Major adverse reactions (which occur with much less frequency than the minor adverse reactions) include inhibition of myelopoiesis (agranulocytosis, granulocytopenia, thrombocytopenia, and aplastic anemia), drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. Nephritis occurs very rarely. There have been postmarketing case reports of acute pancreatitis.

There are reports of a vasculitis, often associated with the presence of anti-neutrophilic cytoplasmic antibodies (ANCA), resulting in severe complications (see WARNINGS). 

Minor adverse reactions include skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy.

To report SUSPECTED ADVERSE REACTIONS, contact Bionpharma Inc. at 1-888-235-BION or 1-888-235-2466 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. Despite effective screening and treatment strategies, screening rates remain at 59-65%. UPHS employees have similarly limited rates of CRC screening despite having awareness, access, and insurance coverage. There is a need to identify those who are not up-to-date on screening and eligible for outreach in this population. Financial incentives informed by behavioral economic principles could be used to encourage self-report about screening status and completion of CRC screening. This research utilizes a digital health platform, Way to Health, to evaluate the feasibility of a cancer health risk assessment. This is a single-center RCT among UPHS employees between ages 50-64 that will randomize eligible participants into one of two study arms: (1) no incentive to complete cancer health risk assessment (no incentive) or (2) loss-framed incentive to complete cancer health risk assessment (incentive). Those that are eligible for screening will receive a direct access phone number to schedule colonoscopy, with an additional unconditional incentive for those in incentive arm. The primary outcome is completion of screening colonoscopy, with secondary outcomes of colonoscopy scheduling and completion of risk assessment.
FIELD: medicine. SUBSTANCE: method involves performing hematoma lavage with solution under excessive hydrodynamic pressure. The solution has thrombin. The cavity is treated with laser power and medicinal mixture containing fibrinogen, thrombin and contrical is introduced into it. Visual control is carried out by means of rigid endoscope. The device to put the invention in practice has inclined nozzle and connecting pipe. EFFECT: prevented redislocation syndrome. 4 cl, 1 dwg
Intervention patients will receive personalized education regarding their condition, pre- and post-testing of their HF knowledge base, and ED standard of care during the enrollment (index) visit. Patients will then be contacted via telephone 30 days post-index visit for re-testing and reinforcement of previously learned material.
The invention includes methods for performing non-surgical lung volume reduction in a patient by (a) administering, through the patient's trachea, a composition comprising an enzyme (e.g., a protease, such as a serine protease (e.g., trypsin, chymotrypsin, elastase, or an MMP), and/or a detergent, and/or a polycation; and (b) collapsing a region of the lung, at least a portion of which was contacted by the composition administered in step (a). The patient can have COPD (e.g., emphysema) or their lung can be damaged by a traumatic event. The tissue in the targeted area can also include an abscess or fistula. One can similarly treat other tissues (i.e., non-lung tissues) by exposing those tissues to an enzyme-containing composition (or other composition described herein). These tissues may be those that are obscured from a therapeutic agent by epithelial cells or that will contact an implantable device. Where the lung is targeted, one can collapse a region of the lung by administering, to the targeted region, a substance that increases the surface tension of fluids lining the alveoli in the targeted region, the surface tension being increased to the point where the region of the lung collapses. The concentration of the active agents in the compositions of the invention are described further below, but we note here that the concentrations will be sufficient to damage the epithelial cell lining of the lung or the epithelium lining or otherwise covering another tissue. The compositions described herein can be used not only for lung volume reduction and other tissue treatments, but also for use as medicaments, or for use in the preparation of medicaments, for treating patients who have a disease or condition that would benefit from selective epithelial damage and subsequent fibrosis or scar formation (e.g., a disease or condition in which the target cells would otherwise be obscured by the epithelial lining of a tissue or one that can be treated with an implanted device (e.g., a stent or a valve, pump, or prosthetic device)).
Implementation of biomarkers in sepsis and septic shock in emergency situations, remains highly challenging. This viewpoint arose from a public-private 3-day workshop aiming to facilitate the transition of sepsis biomarkers into clinical practice. The authors consist of international academic researchers and clinician-scientists and industry experts who gathered (i) to identify current obstacles impeding biomarker research in sepsis, (ii) to outline the important milestones of the critical path of biomarker development and (iii) to discuss novel avenues in biomarker discovery and implementation. To define more appropriately the potential place of biomarkers in sepsis, a better understanding of sepsis pathophysiology is mandatory, in particular the sepsis patient's trajectory from the early inflammatory onset to the late persisting immunosuppression phase. This time-varying host response urges to develop time-resolved test to characterize persistence of immunological dysfunctions. Furthermore, age-related difference has to be considered between adult and paediatric septic patients. In this context, numerous barriers to biomarker adoption in practice, such as lack of consensus about diagnostic performances, the absence of strict recommendations for sepsis biomarker development, cost and resources implications, methodological validation challenges or limited awareness and education have been identified. Biomarker-guided interventions for sepsis to identify patients that would benefit more from therapy, such as sTREM-1-guided Nangibotide treatment or Adrenomedullin-guided Enibarcimab treatment, appear promising but require further evaluation. Artificial intelligence also has great potential in the sepsis biomarker discovery field through capability to analyse high volume complex data and identify complex multiparametric patient endotypes or trajectories. To conclude, biomarker development in sepsis requires (i) a comprehensive and multidisciplinary approach employing the most advanced analytical tools, (ii) the creation of a platform that collaboratively merges scientific and commercial needs and (iii) the support of an expedited regulatory approval process.
In reversible pulpitis group MTA (ProRoot MTA,white) was used in 21 teeth and Biodentine was used in the other 21 teeth for pulpotomy treatments. Final restorations were performed with stainless steel crowns in both group. At the end of 3, 6 and 9 months, all teeth were evaluated clinically and radiographically based on AAPD criteria: (1) absence of spontaneous pain and/or sensitivity to pressure; (2) absence of sinus, fistula, edema, and/or abnormal mobility; (3) absence of radiolucency at the interradicular and/or periapical regions; (4) absence of internal or external root resorption.
The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4  alkyl. The substituent at the 3-position of the 1 -azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.
This multi-center, multiple-arm study will evaluate the microbiological activity and safety of C16G2 Gel in male and female dental subjects, 12 to 75 years of age. The study will be conducted in a randomized, double-blind, placebo-controlled and open-label manner and enroll adolescent (12-17 years of age) and adult subjects (18-75 years of age).

A total of approximately 128 study subjects will be enrolled into up to 7 study arms. Study drug (C16G2 Gel or Placebo) will be administered via manual brush gel application (MBGA) or tray gel application (TGA). Two C16G2 concentrations will be evaluated. Four study arms will be conducted in a double blind manner, with a treatment allocation ratio of 4:1 (C16G2:Placebo), three study arms will be conducted in an open-label manner. Before dosing, eligible subjects will undergo professional dental prophylaxis on Day 0. Clinic visits for all study arms will include Visit 1 (Screening/Days -21 to 0), and a varying number of dosing and follow-up visits.
PCT No. PCT/JP92/01563 Sec. 371 Date Nov. 29, 1994 Sec. 102(e) Date Nov. 29, 1994 PCT Filed Nov. 30, 1992 PCT Pub. No. WO93/14640 PCT Pub. Date Aug. 5, 1993There is disclosed an antimicrobial agent comprising one or more of antimicrobial peptides derived from lactoferrins, and one or more of specific compounds and/or at least an antibiotic, and a method for treating matters with said antimicrobial agent. The antimicrobial agent has a potent antimicrobial activity against wide variety of microorganisms, thus it is useful not only as a medication, but also useful for making antimicrobial treatment of matters such as foods, non-medical products, and the like with safety and great efficiency.
The orofacial treatment group receives therapeutic orofacial treatment in addition to routine physiotherapy treatment. For orofacial therapy, sessions will be conducted twice a week for eight weeks, lasting 30-45 minutes, totaling 16 sessions.
An ophthalmologically acceptable collagen containing aqueous composition is disclosed. The composition contains collagen and is a flowable liquid at temperatures below mammalian eye temperature (32°C to 42°C) and forms a gelled sustained release matrix after administration to the mammalian eye. The composition is comprised of ophthalmologically acceptable collagen material, a pharmaceutically active non-steroidal antiinflammatory drug, optionally an antibiotic, a buffer, a nonionic ethoxylated alkylphenol surfactant, a quaternary ammonium preservative, a tonicifier, a chelating agent, and optional excipients in an aqueous carrier. The collagen in the composition undergoes a change from a flowable liquid to a gelled matrix after the formulation is administered to the eye. The gelled matrix of the formulation traps and physically holds the drug in the matrix. When applied, the gel will remain in place in the cul-de-sac of the eye substantially longer than liquid formulations and will allow for a sustained release method of delivery of the drug to the eye. The drug release from the matrix and the drug half life are such that the formulation allows for once a day or even less frequent dosing which increases the convenience and improves patient compliance.
Stage I periodontitis was diagnosed with interdental attachment loss (AL) ranging between 1 and 2 mm at the site of greatest loss. Radiographic bone loss (BL) is limited to less than 15% and no tooth loss. Additionally, the maximum probing depth (PD) is equal to or less than 4 mm or primarily involves horizontal bone loss. Stage II periodontitis was diagnosed with interdental attachment loss (AL) is ranging between 3 and 4 mm at the site of greatest loss. Radiographic bone loss (BL) extends to a range of 15% to 33%, there is no tooth loss. The maximum probing depth (PD) is equal to or less than 5 mm or primarily involves horizontal bone loss.
ProHance was evaluated in two multicenter trials of 310 evaluable patients suspected of having neurological pathology. After the administration of ProHance 0.1 mmol/kg IV, the results were similar to those described below [see Clinical Studies (14.2)].

In another multicenter study of 49 evaluable adult patients with known intracranial tumor with high suspicion of having cerebral metastases, two doses of ProHance were administered. First ProHance 0.1 mmol/kg was injected followed 30 minutes later with 0.2 mmol/kg. In comparison to the 0.1 mmol/kg dose alone, the addition of the 0.2 mmol/kg dose improved visualization in 67% and improved border definition in 56% of patients. In comparison to non-contrast MRI, the number of lesions after 0.1 mmol/kg increased in 34% of patients. After ProHance 0.2 mmol/kg, this increased to 44%.

Pediatric Patients   
ProHance was evaluated in a multicenter study of 103 patients undergoing brain or spine MRI. Among these patients, the age range was 2 to 20 years; 54 were between 2 and 12 years of age; 74% were Caucasian, 11% Black, 12% Hispanic, 2% Asian, and 2% other. ProHance was given in one single 0.1 mmol/kg dose. Repeat dosing was not studied. The results of the non-contrast and ProHance MRI scans were compared. In this database, MRI enhancement was noted in approximately 60% of the scans and additional diagnostic information in 30 to 95% of the scans.

A prospectively planned study of 125 pediatric patients younger than 2 years of age retrospectively selected was performed. These patients (70 boys and 55 girls) had an age range of 1 day to 24 months old; 17 were less than 1 month of age, 40 were between 1 month and 6 months of age, 29 were between 6 months and 12 months of age, and 39 were between 12 months and 24 months of age; 56% were Caucasian, 25% Black, 5% Asian, and 14% other. ProHance was given in one single 0.1 mmol/kg dose. Repeat dosing was not studied. Three independent, blinded readers evaluated pre-contrast MRI image sets and paired pre-plus-post-contrast MRI image sets using ProHance and rated the images according to three co-primary visualization endpoints: lesion border delineation, visualization of lesion internal morphology, and lesion contrast enhancement. All three blinded readers reported improvement in the paired image sets for each of the three co-primary endpoints.
PROBLEM TO BE SOLVED: To obtain a new isocarbacyclin derivative useful in the search for functions of a prostacyclin receptor in a brain, the specification, etc., of an adaptable region of a prostacyclin derivative in the central nervous system. SOLUTION: This carbacyclin derivative is represented by formula I (R<1> is H, an alkyl or one equiv. cation; R<2> is alkylene) e.g. 16-(3-methylphenyl)-13,14- dihydro-17,18,18,20-tetranoylisocarbacyclin methyl ester represented by formula II. The compound represented by formula I is obtained by carrying out the reducing reaction of, e.g. a compound represented by formula III (R<3> is an alkyl) and further, as necessary, conducting the hydrolytic reaction of the resultant compound.